Company profile
Tilray Brands, Inc.
NASDAQ: TLRY · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Leamington, ONCIK 0001731348Reports USD
#173 of 1,418 Healthcare companies by revenue47th-percentile growth
EA Score
——FH —DQ 61GM —SS 69
v0.1 · 25/100 weight · pillars only
↑ workforce scale, market scale · ↓ return on equity, return on assets
Methodology →Revenue TTM
$1.2B
Rev growth YoY (TTM)
+3.1%
Net income (FY)
-$2.2B
Employees
3,595
as of 2026-08-11
Market cap
$494.3M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$821.3M$821.3M2025
Net income-$2.2B-$2.2B2025
Operating income-$2.3B-$2.3B2025
Total assets$2.1B$2.1B2025
Liabilities$584.8M$584.8M2025
Equity$1.5B$1.5B2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Cannabis36%
Distribution Revenue30%
Beverage Alcohol Business28%
Wellness Business7%
By geography
EMEA39%
UNITED STATES33%
CANADA26%
Rest of World1%
The read
What is Tilray Brands, Inc.’s revenue?
Tilray Brands, Inc. booked $821.3M in FY2025 revenue, growing 4.1% year over year — about the middle of the pack among Healthcare companies we track, at a -266.3% net margin.
Peers · Healthcare
Arrowhead Pharmaceuticals, Inc.76B+Myriad Genetics, Inc.67BOrthofix Medical Inc.75B+Caris Life Sciences, Inc.61CGoodRx Holdings, Inc.68BU.S. Physical Therapy, Inc.80B+Key facts
CEOIrwin David Simon
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersLeamington, ON
ExchangeNASDAQ: TLRY
Employees3,595
IPO date2018-07-19
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.